Rhythm Pharmaceuticals Statistics
Share Statistics
Rhythm Pharmaceuticals has 61.46M shares outstanding. The number of shares has increased by 2.19% in one year.
| Shares Outstanding | 61.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.53% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 54.84M |
| Failed to Deliver (FTD) Shares | 18 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 5.81M, so 9.45% of the outstanding shares have been sold short.
| Short Interest | 5.81M |
| Short % of Shares Out | 9.45% |
| Short % of Float | 10.82% |
| Short Ratio (days to cover) | 11.04 |
Valuation Ratios
The PE ratio is -14.36 and the forward PE ratio is -24.15.
| PE Ratio | -14.36 |
| Forward PE | -24.15 |
| PS Ratio | 34.24 |
| Forward PS | 9.9 |
| PB Ratio | 15.62 |
| P/FCF Ratio | -19.47 |
| PEG Ratio | n/a |
Enterprise Valuation
Rhythm Pharmaceuticals Inc. has an Enterprise Value (EV) of 2.59B.
| EV / Earnings | -14.04 |
| EV / Sales | 33.48 |
| EV / EBITDA | -15.39 |
| EV / EBIT | -14.06 |
| EV / FCF | -19.03 |
Financial Position
The company has a current ratio of 5.58, with a Debt / Equity ratio of 0.
| Current Ratio | 5.58 |
| Quick Ratio | 5.43 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -13.27 |
Financial Efficiency
Return on equity (ROE) is -1.09% and return on capital (ROIC) is -108.13%.
| Return on Equity (ROE) | -1.09% |
| Return on Assets (ROA) | -0.56% |
| Return on Capital (ROIC) | -108.13% |
| Revenue Per Employee | 342.60K |
| Profits Per Employee | -817.16K |
| Employee Count | 226 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 1.08 |
Taxes
| Income Tax | 564.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 32.89% in the last 52 weeks. The beta is 2.09, so Rhythm Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 2.09 |
| 52-Week Price Change | 32.89% |
| 50-Day Moving Average | 58.1 |
| 200-Day Moving Average | 48.11 |
| Relative Strength Index (RSI) | 40.27 |
| Average Volume (20 Days) | 560.40K |
Income Statement
In the last 12 months, Rhythm Pharmaceuticals had revenue of 77.43M and earned -184.68M in profits. Earnings per share was -3.2.
| Revenue | 77.43M |
| Gross Profit | 68.13M |
| Operating Income | -184.36M |
| Net Income | -184.68M |
| EBITDA | -168.46M |
| EBIT | -184.36M |
| Earnings Per Share (EPS) | -3.2 |
Balance Sheet
The company has 60.08M in cash and 1.26M in debt, giving a net cash position of 58.82M.
| Cash & Cash Equivalents | 60.08M |
| Total Debt | 1.26M |
| Net Cash | 58.82M |
| Retained Earnings | -894.74M |
| Total Assets | 363.57M |
| Working Capital | 242.74M |
Cash Flow
In the last 12 months, operating cash flow was -136.16M and capital expenditures -47.00K, giving a free cash flow of -136.20M.
| Operating Cash Flow | -136.16M |
| Capital Expenditures | -47.00K |
| Free Cash Flow | -136.20M |
| FCF Per Share | -2.36 |
Margins
Gross margin is 87.99%, with operating and profit margins of -238.1% and -238.52%.
| Gross Margin | 87.99% |
| Operating Margin | -238.1% |
| Pretax Margin | -237.79% |
| Profit Margin | -238.52% |
| EBITDA Margin | -217.58% |
| EBIT Margin | -238.1% |
| FCF Margin | -175.91% |
Dividends & Yields
RYTM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5.93% |
| FCF Yield | -4.11% |
Analyst Forecast
The average price target for RYTM is $67.5, which is 25.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $67.5 |
| Price Target Difference | 25.1% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 0.76 |
| Piotroski F-Score | 2 |